With semaglutide therapy now widely available, a newer contender called retatrutide has emerged from clinical trials with results that could redefine what is possible with anti-obesity medications
Introduction The postpartum period is a time of incredible transformation and physical demand
It calls the result a signal for caution rather than a settled answer
The reported treatment effect for patients with a BMI of 30 or less, patients without a history of MI or stroke before randomization, and patients exhibiting CV risk factors (only, as opposed to CV disease) may suggest a lower risk of time to first MACE in these subgroup populations
By understanding how Semaglutide affects stomach size, individuals and healthcare providers can make informed decisions about its use in weight loss
Cardiometabolic Biomarker Research Researchers also use retatrutide to study broader cardiometabolic biomarker responses associated with integrated endocrine signaling